A multiplexed, targeted mass spectrometry assay of the S100 protein family uncovers the isoform-specific expression in thyroid tumours

BMC Cancer

Juan Martínez-Aguilar¹  Roderick Clifton-Bligh²  Mark P Molloy¹ 

[1] Australian Proteome Analysis Facility, Macquarie University, Sydney 2109, NSW, Australia

[2] Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, Sydney 2065, NSW, Australia

关键词: Tumour tissue samples;    Thyroid cancer;    Mass spectrometry;    Selected reaction monitoring;    S100 proteins;   

Others  :  1161231
DOI  :  10.1186/s12885-015-1217-x

 received in 2014-12-11, accepted in 2015-03-18,  发布年份 2015

【 摘 要 】

Background

Mounting evidence demonstrates a causal role for S100 proteins in tumourigenesis and several S100 isoforms have shown utility as biomarkers of several types of cancer. The S100 family is comprised of 21 small isoforms, many of them implicated in important cellular functions such as proliferation, motility and survival. Furthermore, in vivo experiments have proven the role of S100 proteins in tumour growth and disease progression, while other studies have shown their prognostic value and involvement in resistance to chemotherapy drugs. Taken together, all these aspects highlight S100 proteins as potential therapeutic targets and as a promising panel of cancer biomarkers. In this work, we have developed a mass spectrometry (MS)-based method for the multiplexed and specific analysis of the entire S100 protein family in tumour tissues and have applied it to investigate the expression of S100 isoforms in the context of thyroid cancer, the main endocrine malignancy.

Methods

Selected Reaction Monitoring (SRM)-MS and stable isotope labelling/label-free analysis were employed to investigate the expression of the 21 S100 protein isoforms in thyroid tissue samples. Specimens included 9 normal thyroid tissues and 27 tumour tissues consisting of 9 follicular adenomas (FA), 8 follicular carcinomas (FTC) and 10 papillary carcinomas (PTC).

Results

The multiplexed and targeted mass spectrometry method led to the detection of eleven S100 protein isoforms across all tissues. Label- and label-free analyses showed the same significant differences and results were confirmed by western blot. S100A6, S100A11 and its putative interaction partner annexin A1 showed the highest overexpression in PTC compared to normal thyroid. S100A13 was also elevated in PTC. Reduced S100A4 expression was observed in FA compared to all other tissues. FA and FTC showed reduction of S100A10 and annexin A2 expression.

Conclusions

Targeted mass spectrometry allows the multiplexed and specific analysis of S100 protein isoforms in tumour tissue specimens. It revealed S100A13 as a novel candidate PTC biomarker. Results show that S100A6, S100A11 and Annexin A1 could help discriminate follicular and papillary tumours. The diagnostic and functional significance of S100A4 and S100A10 reduction in follicular tumours requires further investigation.

【 授权许可】

   
2015 Martínez-Aguilar et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Salama I, Malone PS, Mihaimeed F, Jones JL: A review of the S100 proteins in cancer. Eur J Surg Oncol 2008, 34(4):357-64.
• [2]Chen H, Xu C, Jin Q, Liu Z: S100 protein family in human cancer. Am J Cancer Res 2014, 4(2):89-115.
• [3]Gross SR, Sin CG, Barraclough R, Rudland PS: Joining S100 proteins and migration: for better or for worse, in sickness and in health. Cell Mol Life Sci 2014, 71(9):1551-79.
• [4]Marenholz I, Heizmann CW, Fritz G: S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 2004, 322(4):1111-22.
• [5]Sedaghat F, Notopoulos A: S100 protein family and its application in clinical practice. Hippokratia 2008, 12(4):198-204.
• [6]Huang L, Xu Y, Cai G, Guan Z, Sheng W, Lu H, et al.: S100A4 over-expression underlies lymph node metastasis and poor prognosis in colorectal cancer. World J of Gastroenterol 2011, 17(1):69-78.
• [7]Rudland PS, Platt-Higgins A, Renshaw C, West CR, Winstanley JH, Robertson L, et al.: Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer. Cancer Res 2000, 60(6):1595-603.
• [8]Wang YY, Ye ZY, Zhao ZS, Tao HQ, Chu YQ: High-level expression of S100A4 correlates with lymph node metastasis and poor prognosis in patients with gastric cancer. Ann Surg Oncol 2010, 17(1):89-97.
• [9]Tsukamoto N, Egawa S, Akada M, Abe K, Saiki Y, Kaneko N, et al.: The expression of S100A4 in human pancreatic cancer is associated with invasion. Pancreas 2013, 42(6):1027-33.
• [10]Saleem M, Kweon MH, Johnson JJ, Adhami VM, Elcheva I, Khan N, et al.: S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9. Proc Natl Acad Sci U S A 2006, 103(40):14825-30.
• [11]Cross SS, Hamdy FC, Deloulme JC, Rehman I: Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology 2005, 46(3):256-69.
• [12]Komatsu K, Andoh A, Ishiguro S, Suzuki N, Hunai H, Kobune-Fujiwara Y, et al.: Increased expression of S100A6 (Calcyclin), a calcium-binding protein of the S100 family, in human colorectal adenocarcinomas. Clin Cancer Res 2000, 6(1):172-7.
• [13]Yang YQ, Zhang LJ, Dong H, Jiang CL, Zhu ZG, Wu JX, et al.: Upregulated expression of S100A6 in human gastric cancer. J Dig Dis. 2007, 8(4):186-93.
• [14]Ohuchida K, Mizumoto K, Yu J, Yamaguchi H, Konomi H, Nagai E, et al.: S100A6 is increased in a stepwise manner during pancreatic carcinogenesis: clinical value of expression analysis in 98 pancreatic juice samples. Cancer Epidemiol Biomarkers Prev 2007, 16(4):649-54.
• [15]Rehman I, Cross SS, Azzouzi AR, Catto JW, Deloulme JC, Larre S, et al.: S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursors. Br J Cancer 2004, 91(4):739-44.
• [16]Arai K, Takano S, Teratani T, Ito Y, Yamada T, Nozawa R: S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. Curr Cancer Drug Targets 2008, 8(4):243-52.
• [17]Duan L, Wu R, Ye L, Wang H, Yang X, Zhang Y, et al.: S100A8 and S100A9 are associated with colorectal carcinoma progression and contribute to colorectal carcinoma cell survival and migration via Wnt/beta-catenin pathway. PLoS One 2013, 8(4):e62092.
• [18]Wang L, Chang EW, Wong SC, Ong SM, Chong DQ, Ling KL: Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J Immunol 2013, 190(2):794-804.
• [19]Shen J, Person MD, Zhu J, Abbruzzese JL, Li D: Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 2004, 64(24):9018-26.
• [20]Hermani A, Hess J, De Servi B, Medunjanin S, Grobholz R, Trojan L, et al.: Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res 2005, 11(14):5146-52.
• [21]Meding S, Balluff B, Elsner M, Schone C, Rauser S, Nitsche U, et al.: Tissue-based proteomics reveals FXYD3, S100A11 and GSTM3 as novel markers for regional lymph node metastasis in colon cancer. J Pathol. 2012, 228(4):459-70.
• [22]Liu XG, Wang XP, Li WF, Yang S, Zhou X, Li SJ, et al.: Ca2 + -binding protein S100A11: a novel diagnostic marker for breast carcinoma. Oncol Rep 2010, 23(5):1301-8.
• [23]Mori M, Shimada H, Gunji Y, Matsubara H, Hayashi H, Nimura Y, et al.: S100A11 gene identified by in-house cDNA microarray as an accurate predictor of lymph node metastases of gastric cancer. Oncol Rep 2004, 11(6):1287-93.
• [24]Ohuchida K, Mizumoto K, Ohhashi S, Yamaguchi H, Konomi H, Nagai E, et al.: S100A11, a putative tumor suppressor gene, is overexpressed in pancreatic carcinogenesis. Clin Cancer Res 2006, 12(18):5417-22.
• [25]Rehman I, Azzouzi AR, Cross SS, Deloulme JC, Catto JW, Wylde N, et al.: Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions. Hum Pathol 2004, 35(11):1385-91.
• [26]Dong L, Wang F, Yin X, Chen L, Li G, Lin F, et al.: Overexpression of S100P promotes colorectal cancer metastasis and decreases chemosensitivity to 5-FU in vitro. Mol Cell Biochem 2014, 389(1–2):257-64.
• [27]Maciejczyk A, Lacko A, Ekiert M, Jagoda E, Wysocka T, Matkowski R, et al.: Elevated nuclear S100P expression is associated with poor survival in early breast cancer patients. Histol Histopathol 2013, 28(4):513-24.
• [28]Ge F, Wang C, Wang W, Wu B: S100P predicts prognosis and drug resistance in gastric cancer. Int J Biol Markers 2013, 28(4):5000034.
• [29]Basu GD, Azorsa DO, Kiefer JA, Rojas AM, Tuzmen S, Barrett MT, et al.: Functional evidence implicating S100P in prostate cancer progression. Int J Cancer 2008, 123(2):330-9.
• [30]Arumugam T, Simeone DM, Van Golen K, Logsdon CD: S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res 2005, 11(15):5356-64.
• [31]Ribe A, McNutt NS: S100A6 protein expression is different in Spitz nevi and melanomas. Mod Pathol 2003, 16(5):505-11.
• [32]Massi D, Landriscina M, Piscazzi A, Cosci E, Kirov A, Paglierani M, et al.: S100A13 is a new angiogenic marker in human melanoma. Mod Pathol 2010, 23(6):804-13.
• [33]Hamberg AP, Korse CM, Bonfrer JM, de Gast GC: Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res 2003, 13(1):45-9.
• [34]Bulk E, Sargin B, Krug U, Hascher A, Jun Y, Knop M, et al.: S100A2 induces metastasis in non-small cell lung cancer. Clin Cancer Res 2009, 15(1):22-9.
• [35]Davies BR, O'Donnell M, Durkan GC, Rudland PS, Barraclough R, Neal DE, et al.: Expression of S100A4 protein is associated with metastasis and reduced survival in human bladder cancer. J Pathol 2002, 196(3):292-9.
• [36]Zhang H, Zhao Q, Chen Y, Wang Y, Gao S, Mao Y, et al.: Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas. Thorax 2008, 63(4):352-9.
• [37]Chen H, Ma J, Sunkel B, Luo A, Ding F, Li Y, et al.: S100A14: novel modulator of terminal differentiation in esophageal cancer. Mol Cancer Res 2013, 11(12):1542-53.
• [38]Gongoll S, Peters G, Mengel M, Piso P, Klempnauer J, Kreipe H, et al.: Prognostic significance of calcium-binding protein S100A4 in colorectal cancer. Gastroenterology 2002, 123(5):1478-84.
• [39]Sack U, Walther W, Scudiero D, Selby M, Kobelt D, Lemm M, et al.: Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer. J Natl Cancer Inst 2011, 103(13):1018-36.
• [40]Stein U, Arlt F, Smith J, Sack U, Herrmann P, Walther W, et al.: Intervening in beta-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis. Neoplasia 2011, 13(2):131-44.
• [41]Wang XH, Zhang LH, Zhong XY, Xing XF, Liu YQ, Niu ZJ, et al.: S100A6 overexpression is associated with poor prognosis and is epigenetically up-regulated in gastric cancer. Am J Pathol 2010, 177(2):586-97.
• [42]Zhang J, Zhang K, Jiang X, Zhang J: S100A6 as a potential serum prognostic biomarker and therapeutic target in gastric cancer. Dig Dis Sci 2014, 59(9):2136-44.
• [43]Dakhel S, Padilla L, Adan J, Masa M, Martinez JM, Roque L, et al.: S100P antibody-mediated therapy as a new promising strategy for the treatment of pancreatic cancer. Oncogenesis 2014, 3:e92.
• [44]Cancemi P, Di Cara G, Albanese NN, Costantini F, Marabeti MR, Musso R, et al.: Large-scale proteomic identification of S100 proteins in breast cancer tissues. BMC Cancer 2010, 10:476.
• [45]Martínez-Aguilar J, Molloy MP: Label-free Selected Reaction Monitoring enables multiplexed quantitation of S100 protein isoforms in cancer cells. J Proteome Res 2013, 12(8):3679-88.
• [46]Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al.: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19(11):1167-214.
• [47]Baloch ZW, Cibas ES, Clark DP, Layfield LJ, Ljung BM, Pitman MB, et al.: The National Cancer Institute Thyroid fine needle aspiration state of the science conference: a summation. Cytojournal 2008, 5(6):1742-6413.
• [48]Abbatiello SE, Mani DR, Keshishian H, Carr SA: Automated detection of inaccurate and imprecise transitions in peptide quantification by multiple reaction monitoring mass spectrometry. Clin Chem 2010, 56(2):291-305.
• [49]Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al.: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3(7):18.
• [50]Eisenberg E, Levanon EY: Human housekeeping genes, revisited. Trends Genet 2013, 29(10):569-74.
• [51]de Jonge HJ, Fehrmann RS, de Bont ES, Hofstra RM, Gerbens F, Kamps WA, et al.: Evidence based selection of housekeeping genes. PLoS One 2007, 2(9):e898.
• [52]Shcherbik N, Pestov DG: Ubiquitin and ubiquitin-like proteins in the nucleolus: multitasking tools for a ribosome factory. Genes Cancer 2010, 1(7):681-9.
• [53]Voges D, Zwickl P, Baumeister W: The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 1999, 68:1015-68.
• [54]Stavreva DA, Kawasaki M, Dundr M, Koberna K, Muller WG, Tsujimura-Takahashi T, et al.: Potential roles for ubiquitin and the proteasome during ribosome biogenesis. Mol Cell Biol 2006, 26(13):5131-45.
• [55]Dai RM, Li CC: Valosin-containing protein is a multi-ubiquitin chain-targeting factor required in ubiquitin-proteasome degradation. Nat Cell Biol 2001, 3(8):740-4.
• [56]Lange V, Picotti P, Domon B, Aebersold R: Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol 2008, 4:222.
• [57]Sofiadis A, Dinets A, Orre LM, Branca RM, Juhlin CC, Foukakis T, et al.: Proteomic study of thyroid tumors reveals frequent up-regulation of the Ca2+ -binding protein S100A6 in papillary thyroid carcinoma. Thyroid 2010, 20(10):1067-76.
• [58]Anania MC, Miranda C, Vizioli MG, Mazzoni M, Cleris L, Pagliardini S, et al.: S100A11 overexpression contributes to the malignant phenotype of papillary thyroid carcinoma. J Clin Endocrinol Metab 2013, 98(10):2013-1652.
• [59]Seemann J, Weber K, Gerke V: Structural requirements for annexin I-S100C complex-formation. Biochem J 1996, 319(Pt 1):123-9.
• [60]Rescher U, Gerke V: S100A10/p11: family, friends and functions. Pflugers Arch 2008, 455(4):575-82.
• [61]Zhang H, Liu Q, Zimmerman LJ, Ham AJ, Slebos RJ, Rahman J, et al.: Methods for peptide and protein quantitation by liquid chromatography-multiple reaction monitoring mass spectrometry. Mol Cell Proteomics 2011, 10(6):27.
• [62]Sofiadis A, Becker S, Hellman U, Hultin-Rosenberg L, Dinets A, Hulchiy M, et al.: Proteomic profiling of follicular and papillary thyroid tumors. Eur J Endocrinol 2012, 166(4):657-67.
• [63]Gerber SA, Rush J, Stemman O, Kirschner MW, Gygi SP: Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Nat Acad Sci 2003, 100(12):6940-5.
• [64]Pierce A, Barron N, Linehan R, Ryan E, O'Driscoll L, Daly C, et al.: Identification of a novel, functional role for S100A13 in invasive lung cancer cell lines. Eur J Cancer 2008, 44(1):151-9.
• [65]Prudovsky I, Mandinova A, Soldi R, Bagala C, Graziani I, Landriscina M, et al.: The non-classical export routes: FGF1 and IL-1alpha point the way. J Cell Sci 2003, 116(Pt 24):4871-81.
• [66]Eggo MC, Hopkins JM, Franklyn JA, Johnson GD, Sanders DS, Sheppard MC: Expression of fibroblast growth factors in thyroid cancer. J Clin Endocrinol Metab 1995, 80(3):1006-11.
• [67]Brooks AN, Kilgour E, Smith PD: Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 2012, 18(7):1855-62.
• [68]Azimi A, Pernemalm M, Frostvik Stolt M, Hansson J, Lehtio J, Egyhazi Brage S, et al.: Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance. Br J Cancer 2014, 110(10):2489-95.
• [69]Ito Y, Yoshida H, Tomoda C, Uruno T, Miya A, Kobayashi K, et al.: S100A4 expression is an early event of papillary carcinoma of the thyroid. Oncology 2004, 67(5–6):397-402.
• [70]Schmidt-Hansen B, Klingelhofer J, Grum-Schwensen B, Christensen A, Andresen S, Kruse C, et al.: Functional significance of metastasis-inducing S100A4(Mts1) in tumor-stroma interplay. J Biol Chem 2004, 279(23):24498-504.
• [71]Mishra SK, Siddique HR, Saleem M: S100A4 calcium-binding protein is key player in tumor progression and metastasis: preclinical and clinical evidence. Cancer Metastasis Rev 2012, 31(1–2):163-72.
• [72]Shi Y, Zou M, Collison K, Baitei EY, Al-Makhalafi Z, Farid NR, et al.: Ribonucleic acid interference targeting S100A4 (Mts1) suppresses tumor growth and metastasis of anaplastic thyroid carcinoma in a mouse model. J Clin Endocrinol Metab 2006, 91(6):2373-9.
• [73]Ito Y, Arai K, Nozawa R, Yoshida H, Higashiyama T, Takamura Y, et al.: S100A10 expression in thyroid neoplasms originating from the follicular epithelium: contribution to the aggressive characteristic of anaplastic carcinoma. Anticancer Res 2007, 27(4C):2679-83.